Mutations in the lipid-binding domain of α-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity

Molecular and Cellular Neuroscience

Volumn 24, Issue 1, 2003, Pages 91-105

  Wersinger, Christophe ^a   Prou, Delphine ^b   Vernier, Philippe ^b   Niznik, Hyman B ^c   Sidhu, Anita ^a,d  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CNRS   (France)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID; COMPLEMENTARY DNA; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; LIPID; MUTANT PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINE UPTAKE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERMETHOD COMPARISON; MISSENSE MUTATION; MUTATION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; WESTERN BLOTTING; WILD TYPE;

EID: 0141726844     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-7431(03)00124-6     Document Type: Article

References (64)

1. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M.Y., Trojanowski J.Q., Iwatsubo Y. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152:1998;879-884.
2. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2001;135-172.
3. Chan P., Jiang X., Forno L.S., DiMonte D.A., Tanner C.M., Langston J.W. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology. 50:1998;1136-1137.
4. Chandra S., Chen X., Rizo J., Jahn R., Sudhof T.C., 2003. A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem. [epub ahead of print].
5. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:1998;249-254.
6. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4:1998;1318-1320.
7. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA. 97:2000;571-576.
8. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 294:2001;1346-1349.
9. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273:1998;9443-9449.
10. Dawson V.L., Brahmbhatt H.P., Mong J.A., Dawson T.M. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology. 33:1994;1425-1430.
11. El-Agnaf O.M., Jakes R., Curran M.D., Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440:1998;67-70.
12. El-Agnaf O.M., Irvine G.B. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 130:2000;300-309.
13. Eliezer D., Kutluay E., Bussell R. Jr., Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307:2001;1061-1073.
14. Gai W.P., Power J.H.T., Blumberg P.C., Blessing W.W. Multiple-system atrophy: a new alpha-synuclein disease? Lancet. 352:1998;547-548.
15. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 34:2002;521-533.
16. Goedert M., Spillantini M.G. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol. Psychiatry. 3:1998;462-465.
17. Goedert M., Spillantini M.G., Davies S.W. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr. Opin. Neurobiol. 8:1998;619-632.
18. Gosavi N., Lee H.J., Lee J.S., Patel S., Lee S.J. Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277:2002;48984-48992.
19. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport. 10:1999;717-721.
20. Irizarry M.C., Growdon W., Gomez-Isla T., Newell K., George J.M., Clayton D.F., Hyman B.T. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57:1998;334-337.
21. Jakowec M.W., Donaldson D.M., Barba J., Petzinger G.M. Postnatal expression of alpha-synuclein protein in rodent substantia nigra and striatum. Dev. Neurosci. 23:2001;91-99.
22. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273:1998;26292-26294.
23. Jo E., Fuller N., Rand R.P., St. George-Hyslop P., Fraser P.E. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J. Mol. Biol. 315:2002;799-807.
24. Jo E., McLaurin J., Yip C.M., St. George-Hyslop P., Fraser P.E. Alpha-synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275:2000;34328-34334.
25. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320:2002;146-150.
26. Klein R.L., King M.A., Hamby M.E., Meyer E.M. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13:2002;605-612.
27. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108.
28. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15:2001;916-926.
29. Lee H.J., Lee S.J. Characterization of cytoplasmic alpha-synuclein aggregates: fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277:2002;48976-48983.
30. Lee M.H., Hyun D.H., Halliwell B., Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76:2001;998-1009.
31. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA. 99:2002;8968-8973.
32. Li J., Uversky V.N., Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry. 40:2001;11604-11613.
33. Li J.Y., Henning Jensen P., Dahlstrom A. Differential localization of alpha, beta- and gamma-synucleins in the rat CNS. Neuroscience. 113:2002;463-478.
34. Lippa C.F., Schmidt M.L., Lee V.M., Trojanowski J.Q. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45:1999;353-357.
35. Lo Bianco C.L., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 99:2002;10813-10818.
36. Loo D.T., Rillema J.R. Measurement of cell death. Methods Cell Biol. 57:1998;251-264.
37. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology. 58:2002;179-185.
38. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274:1999;9843-9846.
39. - neurotransmitter transporters. J. Neurochem. 71:1998;1785-1803.
40. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6054.
41. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M., Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 20:2001;8053-8061.
42. Perrin R.J., Woods W.S., Clayton D.F., George J.M. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 275:2000;34393-34398.
43. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
44. Prou D., Gu W.J., Le Crom S., Vincent J.D., Salamero J., Vernier P. Intracellular retention of the two isoforms of the D(2) dopamine receptor promotes endoplasmic reticulum disruption. J. Cell Sci. 114:2001;3517-3527.
45. Rockenstein E., Mallory M., Hashimoto M., Song D., Shults C.W., Lang I., Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68:2002;568-578.
46. Sidhu A., Kimura K., Uh M., White B.H., Patel S. Multiple coupling of human D5 dopamine receptors to guanine nucleotide binding proteins Gs and Gz. J. Neurochem. 70:1998;2459-2467.
47. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers: implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275:2000;18344-18349.
48. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251:1998;205-208.
49. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA. 95:1998;6469-6473.
50. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N.Y. Acad. Sci. 920:2000;16-27.
51. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
52. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., Masliah E. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am. J. Pathol. 152:1998;367-372.
53. Trojanowski J.Q., Goedert M., Iwatsubo T., Lee V.M. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5:1998;832-837.
54. Trojanowski J.Q., Lee V.M.Y. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55:1998;151-152.
55. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., Lee V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44:1998;415-422.
56. Van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20:2000;6021-6029.
57. Volles M.J., Lansbury P.T. Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 41:2002;4595-4602.
58. Wakabayashi K., Engelender S., Yoshimoto M., Tsuji S., Ross C.A., Takahashi H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47:2000;521-523.
59. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239:1997;45-48.
60. 2 in a human neuroblastoma derived cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants. Neurosci. Lett. 342, 124-128.
61. Wersinger, C., Sidhu, A., 2003b. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 340, 189-192.
62. Zhou W., Hurlbert M.S., Schaack J., Prasad K.N., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866:2000;33-43.
63. Zhou W., Schaack J., Zawada W.M., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 926:2002;42-50.
64. Zhu, M., Fink, A.L., 2003. Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem. 278, 16873-16877.